Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 38Neoplasm Metastasis 37Multiple Myeloma 29Lymphoma 23Colorectal Neoplasms 18Breast Neoplasms 18Pancreatic Neoplasms 17Prostatic Neoplasms 16Myelodysplastic Syndromes 16Lymphoma, Large B-Cell, Diffuse 15Lung Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Burkitt Lymphoma 15Triple Negative Breast Neoplasms 13Melanoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Ovarian Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Sarcoma 10Neuroblastoma 9Neoplasms 9Glioma 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, T-Cell 8Leukemia, Biphenotypic, Acute 8Fallopian Tube Neoplasms 8Endometrial Neoplasms 8Myeloproliferative Disorders 7Lymphoma, Non-Hodgkin 7

Interventions

Specimen Handling 2Biopsy 2Azacitidine 2venetoclax 1veliparib 1pevonedistat 1peginterferon alfa-2b 1fludarabine phosphate 1axatilimab 1Whole-Body Irradiation 1Topotecan 1Tacrolimus 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Hyperbaric Oxygenation 1Etoposide 1Cyclosporine 1Cyclophosphamide 1Carboplatin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × Biopsy × 90 days × Clear all
NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
35 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡